Eiropas Savienība - latviešu - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velaglucerase alfa - gošē slimība - citas gremošanas trakta un metabolisma produkti, - vpriv ir indicēts ilgstošai enzīmu aizstājterapijai (ert) pacientiem ar 1. tipa gošē slimību.

Latvija - latviešu - Zāļu valsts aģentūra

actavis group ptc ehf., iceland - kapecitabīns - apvalkotās tabletes - 150 mg

Latvija - latviešu - Zāļu valsts aģentūra

actavis group ptc ehf., iceland - kapecitabīns - apvalkotās tabletes - 500 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiski līdzekļi - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiski līdzekļi - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiski līdzekļi - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

centus biotherapeutics europe limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell - antineoplastiski līdzekļi - bevacizumabs kombinācijā ar fluorpirimidīnu saturošu ķīmijterapiju ir indicēts pieaugušiem pacientiem ar metastātisku kakla vai taisnās zarnas vēzi. uz bevacizumab kopā ar paclitaxel ir norādīts uz pirmās līnijas ārstēšanai pieaugušiem pacientiem ar metastātisku krūts vēzi. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. uz bevacizumab kopā ar capecitabine ir norādīts uz pirmās līnijas ārstēšanai pieaugušiem pacientiem ar metastātisku krūts vēzi, kuriem ārstēšana ar citiem ķīmijterapijas iespējas, ieskaitot taxanes vai anthracyclines netiek uzskatīta par piemērotu,. patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with equidacent in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. uz bevacizumab, kopā ar erlotinib, ir norādīts uz pirmās līnijas ārstēšanai pieaugušiem pacientiem ar unresectable papildu metastāžu vai periodiskās ne-plakanšūnu nav maza šūnu plaušu vēzis ar epidermas augšanas faktora receptoru (egfr) aktivizēšana mutācijas. bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. uz bevacizumab, kopā ar paclitaxel un cisplatin vai, alternatīvi, paclitaxel un topotecan pacientiem, kuri nevar saņemt platīna terapiju, ir norādīts ārstēšanai pieaugušiem pacientiem ar pastāvīgu, kas atkārtojas, vai metastātiska dzemdes kakla karcinomu.

Latvija - latviešu - Zāļu valsts aģentūra

aurobindo pharma (malta) limited, malta - valganciklovīrs - apvalkotās tabletes - 450 mg

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - kvetiapīns - ilgstošās darbības tablete - 50 mg

Latvija - latviešu - Zāļu valsts aģentūra

ratiopharm gmbh, germany - latanoprosts - acu pilieni, šķīdums - 50 µg/ml